Safety and Immunogenicity of Hepatitis A Vaccine in Human Immunodeficiency Virus–Infected Patients: A Double‐Blind, Randomized, Placebo‐Controlled Trial | Zendy

Carol A. Kemper | Zendy; Richard Haubrich | Zendy; Ian Frank | Zendy; Gary Dubin | Zendy; Charles Buscarino | Zendy; J. Allen McCutchan | Zendy; Stanley C. Deresinski | Zendy

Open Access

Safety and Immunogenicity of Hepatitis A Vaccine in Human Immunodeficiency Virus–Infected Patients: A Double‐Blind, Randomized, Placebo‐Controlled Trial

Author(s) -

Carol A. Kemper,

Richard Haubrich,

Ian Frank,

Gary Dubin,

Charles Buscarino,

J. Allen McCutchan,

Stanley C. Deresinski

Publication year - 2003

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/374562

Subject(s) - immunogenicity , hepatitis a vaccine , seroconversion , medicine , virology , hepatitis a , immunology , placebo , viral disease , virus , hepatitis , antibody , pathology , alternative medicine

The safety and immunogenicity of inactivated hepatitis A (HepA) vaccine was assessed in 133 hepatitis A virus-seronegative, human immunodeficiency virus (HIV)-infected adults. Patients were randomly assigned to receive, in a blinded fashion, either 2 doses of vaccine (1440 enzyme-linked immunosorbent assay units) or placebo 6 months apart. Seroconversion at month 9 was observed in 68% of those with CD4 cell counts >/=200 cells/mm(3) but in only 9% of those with lower CD4 cell counts (P=.004). HepA vaccine was well tolerated and had no effect on the course of HIV infection or plasma HIV RNA load.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research